BioMarin settles patent suit with Ascendis; wins 20% US royalty on TransCon CNP through May 2030

BIOMARIN PHARMACEUTICAL INC

BioMarin grants Ascendis a non-exclusive, worldwide, transferable, royalty-bearing license to BioMarin Patent Rights covering navepegritide (TransCon CNP)/Yuviwel, effective August 28, 2026.
Royalty is 20% of annual US net sales and 18% of net sales in the EU, Brazil and South Korea, running from first commercial sale in each territory until May 2030.
All pending litigation between the parties over the BioMarin Patent Rights will be dismissed with prejudice; BioMarin releases pre-effective-date infringement claims and covenants not to sue Ascendis.
Ascendis covenants not to challenge BioMarin's Patent Rights, plus a mutual regulatory non-interference clause; licensed products cover achondroplasia and hypochondroplasia, alone or in combination.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.